XML 15 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Cash flows from operating activities:    
Net loss $ (18,399) $ (17,127)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 1,618 794
Amortization of deferred financing costs and debt discount 580 714
Joint Venture acquisition obligation accretion 0 24
Provision for expired inventory 413 26
Stock-based compensation expense 588 925
Loss on asset disposal 9 2
Increases (decreases) in cash caused by changes in operating assets and liabilities:    
Accounts receivable 991 91
Inventories 457 190
Other current assets (284) 205
Other assets 74 32
Accounts payable and accrued expenses (1,746) (1,013)
Deferred revenues 6 (8)
Long-term deferred rent 103 (227)
Net cash used in operating activities (13,904) (15,372)
Cash flows from investing activities:    
Purchases of property and equipment /long-lived assets (271) (110)
Proceeds from sale of assets 10 0
Change in restricted cash (79) 0
Net cash used in investing activities (1,541) (110)
Cash flows from financing activities:    
Principal payments on long-term obligations (4,720) 0
Joint Venture purchase payments 0 (1,774)
Proceeds from sale of common stock, net 12,377 17,702
Net cash provided by financing activities 7,657 15,928
Effect of exchange rate changes on cash and cash equivalents 11 140
Net (decrease) increase in cash and cash equivalents (7,777) 586
Cash and cash equivalents at beginning of period 12,560 14,338
Cash and cash equivalents at end of period 4,783 14,924
Cash paid during period for:    
Interest 1,059 1,213
Azaya Therapeutics, Inc. [Member]    
Adjustments to reconcile net loss to net cash used in operating activities:    
In process research and development acquired 1,686 0
Cash flows from investing activities:    
Purchases of property and equipment /long-lived assets (1,201) 0
Supplemental schedule of non-cash investing and financing activities:    
Common stock issued in payment for the assets acquired $ 2,311 $ 0